17607-70-4Relevant academic research and scientific papers
HIGHLY ACTIVE STING PROTEIN AGONIST COMPOUND
-
Paragraph 0426-0429, (2021/07/17)
The present invention provides compounds of Formula (I) or (II), pharmaceutical compositions thereof, and methods of using compounds of Formula (I) or (II) to prevent and/or treat immune-related disorders.
STING PYRAZOLE AGONISTS AND USES THEREOF
-
Paragraph 00427, (2020/07/14)
The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.
STING AGONISTS AND USES THEREOF
-
Paragraph 00502; 00608, (2020/07/14)
The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.
METHODS FOR ADMINISTERING STING AGONISTS
-
Page/Page column 67-68, (2019/04/27)
The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.
MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV
-
Page/Page column 207, (2019/04/27)
Disclosed are compounds having the formula: (I-N) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof, along with combinations thereof, all of which are useful in HIV therapies.
HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS
-
Page/Page column 190, (2017/11/06)
Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
